ALTERITY THERAPEUTICS

Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

08 مارس 2023 04:25:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial

16 فبراير 2023 13:44:36 بحسب Nasdaq GlobeNewswire

Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model

30 يناير 2023 04:25:00 بحسب Nasdaq GlobeNewswire

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

25 يناير 2023 04:25:00 بحسب Nasdaq GlobeNewswire